The duration of fluzoparib administration is determined by the patient’s condition, treatment response and the physician’s assessment. The drug is generally taken continuously until disease progression or the onset of intolerable adverse reactions. As a PARP inhibitor, fluzoparib is primarily indicated for the maintenance therapy or post-recurrence treatment of malignant tumors such as ovarian cancer and prostate cancer. The specific treatment course is individualized and must be adjusted in strict accordance with the physician’s advice.
Key Factors Influencing the Duration of Medication
Tumor type and stage
Different tumor types (e.g., ovarian cancer, prostate cancer) and stages (early or advanced) shape the treatment objectives. For example, patients with advanced disease may require long-term medication to control disease progression.
Treatment response
If the drug is effective and no severe adverse reactions occur, physicians may recommend continuous administration; the medication duration may be extended if the tumor shrinks or remains stable.
Tolerability to adverse reactions
Common adverse reactions include anemia, nausea, fatigue and the like. In the case of severe adverse reactions (e.g., myelosuppression), dose reduction, temporary suspension or discontinuation of treatment may be necessary.
Clinical Reference for Common Medication Cycles
Maintenance therapy
Continuous administration until disease progression is generally recommended, and some patients may take the drug for several months to years.
Recurrent or refractory tumors
Regimen adjustments are required based on disease changes, and short-term administration (e.g., several months) may be implemented before efficacy assessment.
Precautions for Medication
Strictly follow the physician’s advice
Fluzoparib is a prescription drug and must be used in accordance with the regimen formulated by the physician. Do not adjust the dose or discontinue the drug without authorization.
Undergo regular reexaminations and monitoring
During treatment, regular blood routine tests, liver and kidney function assessments and imaging evaluations are required to facilitate timely regimen adjustments.
Manage adverse reactions properly
Seek immediate medical attention if severe discomfort occurs (e.g., persistent vomiting, infection). Physicians may suspend or discontinue the drug based on the specific situation.
Medical Guidance
The efficacy and safety of fluzoparib require full management by a professional medical team. Patients should develop an individualized treatment plan under the guidance of an oncologist and maintain regular follow-ups to maximize the therapeutic benefits.
